The SPAC market, largely left for dead after its spectacular 2022-2023 collapse, is quietly having a real comeback in 2026. The vehicle priced 55 new IPOs raising a combined $9.8 billion in the second quarter alone -- a level of new-issue activity that would have seemed impossible just two years ago, when redemptions and failed mergers had made SPACs close to uninvestable for institutional capital.
What's different this time is the target profile. RF Acquisition Corp III recently agreed to combine with HCC Healthcare, a Taiwan-based operator of hospitals, clinics, pharmacies and long-term care institutions, at a roughly $500 million pre-transaction equity value -- a real, revenue-generating operating business, not a pre-revenue story stock. JATT II Acquisition Corp struck a $452 million deal with biotech Talawar Tx, and Launch Two Acquisition Corp announced a $579 million combination with NuCube Energy, extending the theme into energy infrastructure. Meanwhile, fresh SPAC capital keeps forming: Samos Energy Acquisition Corporation priced a new $200 million IPO -- 20 million units at $10.00 each -- listing on the NYSE under ticker SAMO.U, specifically to hunt for energy-sector targets.
“The sector mix -- healthcare, biotech, energy -- is itself instructive.”
The sector mix -- healthcare, biotech, energy -- is itself instructive. Unlike 2021's SPAC boom, which was dominated by speculative EV, space and consumer-tech targets with minimal near-term revenue, 2026's SPAC pipeline skews toward companies with identifiable end markets and, in several cases, existing revenue streams. That's a materially more conservative target profile, likely reflecting both tighter SEC scrutiny of SPAC disclosures since 2022 and sponsors' own hard-earned caution after the prior cycle's failures.
For founders and companies considering a public listing, the SPAC market's recovery offers a genuine alternative path back onto the table for the first time in several years -- particularly for capital-intensive, asset-heavy businesses in healthcare, biotech or energy that may not fit the growth-multiple story a traditional tech IPO requires. For investors, the more disciplined target selection is a reason for cautious optimism that this SPAC cycle won't repeat 2021's redemption-driven collapse, though the vehicle's structural conflicts of interest between sponsors and public shareholders haven't disappeared.
The bear case: SPAC economics still create real incentive misalignment between sponsors (who profit from completing any deal) and public shareholders (who profit only from a good deal), and a $9.8 billion quarter is still a fraction of 2021's peak issuance -- this could be a genuine, disciplined recovery or simply a smaller echo of the same cycle. What to watch next: redemption rates on the current wave of SPAC mergers as they close, the real test of whether today's more conservative targets hold up better than 2021's did.